key: cord-0886965-n53unu02
authors: Fang, H.; Wegman, A. D.; Ripich, K.; Friberg, H.; Currier, J.; Thomas, S. J.; Endy, T. P.; Waickman, A.
title: Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2 specific cellular immunity
date: 2021-02-01
journal: nan
DOI: 10.1101/2021.01.29.21250771
sha: 66dd0812774b4d18ae39ccde3887652a48367713
doc_id: 886965
cord_uid: n53unu02

SARS-CoV-2 represents an unprecedented public health challenge with many unknowns remaining regarding the factors that impact viral pathogenicity and the development of immunity after infection. While the majority of SARS-CoV-2 infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, a significant number of individuals experienced prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, especially within the cellular immune compartment. However, it is unclear if persistent mild-to-moderate COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed the development of SARS-CoV-2 specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms, or symptoms persisting for 18 days or more. We observed that the duration of COVID-19 symptoms minimally impacts the magnitude, antigen specificity, and transcriptional profile of SARS-CoV-2 specific cellular immunity within both the CD4+ and CD8+ T cell compartments. Furthermore, we observed that reactivity against the structural N protein from SARS-CoV-2 in convalescent COVID-19 patients correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide additional insight into the complex processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses

INTRODUCTION 72 SARS-CoV-2 is a recently emerged novel single-stranded RNA virus that was initially identified as the 73 causative agent of a pneumonia outbreak in Wuhan, China in early December, 2019 [1] [2] [3] . This initial 74 outbreak has since developed into an unprecedented world-wide pandemic, resulting in an estimated 96 75 million infections and 2 million deaths as of January 2021 . The multi-faceted illness associated with 76 SARS-CoV-2 infection -COVID-19 -is characterized by inflammation of the respiratory tract, fever, 77 musculoskeletal pain, and cough [4] [5] [6] . While SARS-CoV-2-specific humoral and cellular immunity is 78 evident in the majority of patients following the resolution of acute infection and appears to persist for at 79 least 6-8 months [7, 8] , the role of this adaptive immune response in regulating viral replication and 80 disease pathogenesis remains unclear. Furthermore, little is known about how variations in the complex 81 clinical manifestations of COVID-19 impact the development of SARS-CoV-2 specific immunologic 82 memory. 83 84 A notable feature of SARS-CoV-2 infection is that COVID-19 symptoms can persist for weeks or 85 months after initial manifestation even in patients not requiring hospitalization or other medical 86 interventions [9, 10] . This is especially evident in older adults with underlying chronic medical 87 conditions but has been extensively documented in patients across a wide age range [10] . Even in young 88 adults, nearly 20% of patients with confirmed SARS-CoV-2 infection fail to return to full normal daily 89 activities 14-21 days after the onset of COVID-19 symptoms and/or a positive SARS-CoV-2 test in an 90 outpatient setting [11] . Although replication-competent SARS-CoV-2 has been difficult to detect in 91 individuals with protracted COVID-19 symptoms, recovered patients continue to shed detectable SARS-92

CoV-2 RNA in their upper respiratory tract and in their stool for weeks after initial diagnosis [12] [13] [14] . 93 Furthermore, indirect immunologic evidence of SARS-CoV-2 antigen persistence has been observed, 94 most notably reflected in the maturation profile of SARS-CoV-2 specific memory B cells [15] . 95

The presence of persistent viral antigen and/or infection-attendant inflammation is associated with 97 SARS-CoV-2 specific cellular immune response was observed between these two groups when stratified 163 by the duration of self-reported COVID-19 symptoms (Figure 2A, Supplemental Figure 1 ). When 164 further stratified by viral antigen, no difference in the level of reactivity against N, 165 and M was observed between individuals with either a short or long duration of COVID-19 symptoms 166 ( Figure 2B ). A statistically significant higher level of ORF3a and OFR7a reactivity was observed in 167 individuals with longer periods of COVID-19 symptoms than in individuals with a short period of 168 COVID-19 associated symptoms ( Figure 2B ), but most of these responses fell under the 50 SFC/10 6 169 PBMC threshold for positivity ( Table 1) . 170

To further define the profile of SARS-CoV-2 specific cellular immunity and how it stratifies by 172 COVID-19 symptom duration, we assessed the multi-parametric antigen reactivity pattern captured in 173 our ELISPOT analysis. Most individuals included in this analysis exhibited cellular immunity against 174 two-or-more SARS-CoV-2 antigens, with 71.3% of individuals with a short period of COVID-19 175 symptoms and 68.4% of individuals that experienced a long period of COVID symptoms exhibiting a 176 multivalent antigen response ( Figure 2C) . The most common multi-antigen reactivity pattern observed 177 in individuals with a short duration of COVID-19 symptoms was a trivalent response against SARS-178

CoV-2 Spike, N, and M proteins ( Figure 3C ). In contrast, the most common antigen reactivity pattern 179 observed in individuals with a long duration of COVID-19 symptoms was a tetravalent response against 180 SARS-CoV-2 Spike, N, M and ORF3a. 181 182 Flow cytometric assessment of SARS-CoV-2 antigen reactivity. To further define the cellular 183 disposition of the SARS-CoV-2 specific cellular immune response quantified in our ELISPOT analysis, 184 a second aliquot of PBMC from 10 convalescent COVID-19 patients (5 with short symptoms, 5 with 185 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 prolonged symptoms) that were determined to have high levels of SARS-CoV-2 specific cellular 186 immunity were stimulated with a SARS-CoV-2 Spike protein peptide pool and the level of SARS-CoV-187 2 specific cellular immunity quantified by flow cytometry. SARS-CoV-2 reactive CD8+ and CD4+ T 188 cells were identified by their respective upregulation of CD25/CD69 or CD134/CD69 following peptide 189 stimulation. A robust population of SARS-CoV-2 reactive CD8+ T cells were identified in the subjects 190 selected for analysis ( Figure 3A, Supplemental Figure 2) , although the abundance of these cells did 191 not significantly differ when stratified by the duration of COVID-19 symptoms ( Figure 3B) . The 192 magnitude of SARS-CoV-2 Spike protein specific cellular immunity measured by correlated well with the CD8+ T cell SARS-CoV-2 specific cellular immunity as quantified by flow 194 cytometry ( Figure 3C ). In addition to this SARS-Cov-2 Spike protein specific CD8+ T cell response, a 195 quantifiably more robust CD4+ T cell response was observed in all donors ( Figure 3A , Supplemental 196 Figure 2), with most subjects exhibiting a ~50% higher frequency of SARS-CoV-2 Spike reactive CD4 197 T cells than CD8 T cells (Supplemental Figure 3) . Again, the overall magnitude of the SARS-CoV-2 198 specific CD4+ T cell response was not impacted by the duration of 199 there was a very poor correlation between SARS-CoV-2 Spike protein specific CD4+ T cell response as 200 quantified by flow cytometry and the SARs-CoV-2 Spike reactivity as quantified by 201 highlighting the differential utility of the two assays. 202

simulation is known to result in transcriptional-and functional-dysregulation of pathogen-specific T 205 cells and loss of effector function [19] . While no significant difference in the abundance of SARS-CoV-206 2 reactive CD4 and CD8 T cells were noted in the convalescent COVID-19 patients included in this 207 study when stratified by symptom duration, we wished to confirm that the functional transcriptional 208 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250771 doi: medRxiv preprint profile of SARS-CoV-2 reactive CD4+ T cells was not negatively impaired in individuals experiencing 209 prolonged COVID-19 symptoms. Therefore, we sorted SARS-CoV-2 Spike protein reactive CD4 T cells 210 from the 10 donors highlighted above and subjected them to transcriptional profiling. An average of 211 2,322 SARS-CoV-2 reactive CD4+ T cells were isolated from each donor (range 106 -4,497) and were 212 subjected to mRNA sequencing analysis. 213 214 As expected, the cells recovered in this analysis expressed high levels of canonical CD4+ T cell gene 215 products (CD3E, CD4, CD40LG) along with the activation markers used to identify/isolate the cell in 216 the flow cytometry assay ( Figure 4A ). The sorted SARS-CoV-2 specific CD4+ T cells expressed high 217 levels of canonical Th1-assocaited gene products (IFNG, TNF, TBX21), but appreciably lower levels of 218 Th2/Th17 associated transcripts ( Figure 4B ). However, no differentially expressed genes were 219 identified between the samples when segregated by symptom duration, and no appreciable difference 220 was observed in the global transcriptional profile between the two groups ( Figure 4B ). These results 221 suggest that the duration of COVID-19 symptoms minimally impacts the resultant transcriptional profile 222 of SARS-CoV-2 reactive CD4+ T cells in patients recently recovered from mild/moderate 224 Persistent COVID-19 symptoms do not correlate with seasonal coronavirus reactivity. Cellular 225 immunity against SARS-CoV-2 antigens has been observed in PBMC samples collected prior to the 226 emergence of the virus in December 2019 [19] [20] [21] . This has been primarily attributed to cross-reactive 227 cellular immunity elicited by seasonal human coronaviruses such as 229E and NL63 which widely 228 circulate and share some degree of antigen similarity with SARS-CoV-2 [19] . While the impact of pre-229 existing/cross-reactive cellular immunity on the clinical progression of SARS-CoV-2 infection remains 230 unclear, we endeavored to determine if the presence of seasonal human coronavirus specific cellular 231 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021.

immunity in convalescent COVID-19 patients correlated with the duration of self-reported symptoms, 232 and if the magnitude of seasonal human coronavirus cellular immunity correlated with SARS-CoV-2 233 specific cellular immunity. 234

To this end, we utilized overlapping peptide pools spanning the Spike proteins of the human seasonal 236 coronaviruses 229E and NL63 to stimulate PBMC from the same donors described above in a parallel 237 IFN-γ ELISPOT assay. While the majority of subjects exhibited reactivity against the Spike protein from 238 both 229E and NL63, persistent COVID-19 symptoms did not statistically impact magnitude of 229E 239 ( Figure 5A ) or NL63 ( Figure 5B ) Spike protein reactivity as assessed by IFN-γ ELISPOT. While the 240 magnitude of 229E and NL63 reactivity within a given subject correlated with each other, the magnitude 241 of SARS-CoV-2 Spike protein reactivity observed in a given subject does not correlate with their 242 reactivity to Spike from 229E or NL63 (Figure 5C ), suggesting that these cellular populations may be 243 distinct in convalescent COVID-19 patients. Interestingly, despite the lack of correlation between 244 NL63/229E Spike reactivity and SARS-CoV-2 Spike reactivity, the presence of either NL63 or 229E 245

Spike reactivity did correlate with reactivity against the SARS-CoV-2 N protein ( Figure 5C ). Finally, 246 while we noted no significant association between the magnitude of SARS-CoV-2 specific cellular 247 immunity and donor age in our study (Supplemental Figure 4) , a significant negative correlation was 248 observed between the total magnitude of 229E and NL63 reactivity and subject age in our dataset 249 ( Figure 5D) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250771 doi: medRxiv preprint

In this study, we examined the relationship between the duration COVID-19 symptoms and the 256 magnitude and functional profile of SARS-CoV-2 specific cellular immunity in individuals recently 257 recovered from mild/moderate COVID-19. We observed that patients with prolonged COVID-19 258 symptoms overall exhibited similar levels of SARS-CoV-2 specific cellular immunity as individuals 259 who rapidly resolved their symptoms. No defect was observed in the magnitude of the SARS-CoV-2 260

Spike specific CD4 and CD8 T cell response in individuals with prolonged COVID-19 symptoms when 261 assessed using flow cytometry, and the transcription profile of SARS-CoV-2 specific CD4 T cells was 262 observed not to be influenced by the duration of COVID-19 symptoms. Finally, while significant levels 263 of cellular immunity against the seasonal human coronaviruses 229E and NL63 was observed in all 264 convalescent COVID-19 patients analyzed in the study, the magnitude of this immune response did not 265 correlate with the duration of COVID-19 symptoms. These data suggest that prolonged symptomatic 266 COVID-19 does not significantly impact the development of SARS-CoV-2 specific cellular immunity in 267 patients with mild/moderate disease. 268

The development of SARS-CoV-2 specific cellular immunity has been ubiquitously observed following 270 the resolution of COVID-19 symptoms and may be a more sensitive immunologic indication of SARS-271

CoV-2 infection than conventional seroconversion [22, 23] . Indeed, higher levels of both cellular and 272 humoral immunity have been observed in patients after the resolution of severe COVID-19 than 273 following mild or asymptomatic infections [24] . However, the quality of the cellular immune response 274 generated after severe COVID-19 is of uncertain quality, as severe COVID-19 is associated with severe 275 T cell dysregulation, exhaustion, and inflammatory cytokine production [25, 26] . As we did not observe 276 any appreciable deficit in either the quantity or the quality of the SARS-CoV-2 specific cellular immune 277 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250771 doi: medRxiv preprint profile in the individuals analyzed in our study, we feel that it is reasonable to hypothesize that the 278 immunologic mechanisms underpinning severe COVID and persistent mild COVID-19 are distinct and 279 may differentially impact the development of virus-specific cellular memory. 280 281 While it was not unexpected to observe cellular reactivity against coronaviruses other than SARS-CoV-282 2 in the convalescent COVID-19 patients analyzed in our study, the lack of correlation between the 283 magnitude of SARS-CoV-2 Spike protein reactivity and reactivity against Spike from the seasonal 284 coronaviruses 229E and NL63 was unexpected. Preexisting cellular immunity against common seasonal 285 human coronaviruses -such as 229E, NL63, OC43, and HKU1-has been highlighted as the most likely 286 explanation for the relativity high frequency of individuals with SARS-CoV-2 specific cellular 287 immunity prior to the appearance of the virus [19] [20] [21] . Additionally, it is notable that the level of 229E 288 and NL63 Spike reactivity did correlate with the amount of SARS-CoV-2 N reactivity in convalescent 289 COVID-19 patients analyzed in our study. This result is consistent with other previously published 290 reports that suggest that coronavirus infections -including infection with seasonal betacoronaviruses 291 and SARS-CoV -may preferentially result in durable cellular memory against the structural N protein 292 that cross-reacts with SARS-CoV-2 [21] . In addition to providing insight into the mechanisms driving 293 the development of SARS-CoV-2 specific cellular immunity, this observation may provide guidance as 294 to which antigens may be most amenable in the development of a universal coronavirus vaccine. 295 296 297 298 299 300 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. performed under informed consent. All subjects were adults 18 year of age or older who had previously 306 tested positive for SARS-CoV-2 and who were symptom-free for at least 14 days prior to enrollment. 307

Information regarding the timing and duration of acute COVID-19 symptoms -such as fever, shortness 308 of breath, sore throat, cough that impacted activity, and fatigue that impacted activity -were self-309

reported. Lingering symptoms such as loss of taste and smell, mild cough or tickle in the throat, or 310 lingering fatigue that did not impact their daily activity were not considered part of the acute illness and 311 therefore not included in the length of illness. For asymptomatic donors identified via contract tracing 312 protocols the date of positive RT-PCR test was used for the start and stop date of symptoms. Samples 313 were de-identified following collection, and researchers conducting assays were blinded to clinical data 314 until final comparative analysis. PBMC were collected and processed using Vacutainer CPT Cell 315 Preparation Tubes (BD) and stored in vapor phase liquid nitrogen prior to analysis. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250771 doi: medRxiv preprint was mixed with 100 μl of the individuals peptide pools listed in Supplemental Table 2 Table 2) for 18 hours at 37 °C. Spike-reactive CD4 + T cells were identified by expression of the 346 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; immunity in all study participants split by duration of self-report COVID-19 symptoms. C) Correlation 461 table assessing the relationship between NL63, 229E, and SARS-CoV-2 Spike protein reactivity in all 462 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ;

subjects and the magnitude of reactivity against other human coronavirus antigens included in the study. 463 r 2 and p value calculated by 2-tailed Pearson Correlation test. D) Relationship between subject age and 464 total 229E/NL63 Spike protein specific cellular immune response. Filled circles indicate subjects 465 included in the "short" duration of symptoms group. Empty circles indicate individuals included in the 466 "long" duration of symptoms group. r 2 and p value calculated by 2-tailed Pearson Correlation test.  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 23.

Mild COVID-19. Cell, 2020. 183 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.29.21250771 doi: medRxiv preprint 

Genomic characterisation and epidemiology of 2019 novel coronavirus: 511 implications for virus origins and receptor binding

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

We wish to thank all the study participants for making this work possible, Mark Abbott and Kristen 395